var data={"title":"Dimercaptosuccinic acid (succimer): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dimercaptosuccinic acid (succimer): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6991?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-drug-information\" class=\"drug drug_general\">see &quot;Dimercaptosuccinic acid (succimer): Drug information&quot;</a> and <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dimercaptosuccinic acid (succimer): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223371\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Chemet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223372\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Chemet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062370\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Lead Toxicity</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Chelating Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062364\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-drug-information\" class=\"drug drug_general\">see &quot;Dimercaptosuccinic acid (succimer): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Lead poisoning: Note:</b> For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC 2002; ACCLPP 2012). The AAP recommends succimer as the drug used for initial management in asymptomatic children when blood lead levels are &gt;45 mcg/dL and &lt;70 mcg/dL; children with blood lead levels &gt;70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP 2005). Treatment courses may be repeated, but 2-week intervals between courses is generally recommended. Patients who have received calcium disodium EDTA with or without BAL may be treated with succimer after at least 4 weeks have passed since treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Oral: 10 mg/kg/dose (or 350 mg/<b>m<sup>2</sup></b>/dose) every 8 hours for 5 days followed by 10 mg/kg/dose (or 350 mg/<b>m<sup>2</sup></b>/dose) every 12 hours for 14 days; maximum dose: 500 mg/dose. <b>Note: </b> Experts recommend dosing for children &lt;5 years of age should be based on body surface area (AAP 2005; Howland 2015); round doses to the nearest 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Lead poisoning (Kosnett 2007):</b> For the treatment of high blood lead levels in adults, chelation therapy is recommended with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms. Oral: Consider using labeled dose for children: 10 mg/kg/dose (or 350 mg/<b>m<sup>2</sup></b>/dose) every 8 hours for 5 days, followed by 10 mg/kg/dose (or 350 mg/<b>m<sup>2</sup></b>/dose) every 12 hours for 14 days; maximum: 500 mg/dose. <b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Children and Adolescents: ANC &lt;1,200/mm<sup>3</sup>: The manufacturer recommends withholding treatment; treatment may be cautiously resumed when ANC returns to baseline or &gt;1,500/mm<sup>3</sup>. Consultation with a medical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments in the manufacturer&rsquo;s labeling; use with caution and monitor closely. Succimer is dialyzable; however, the lead chelates are not.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children, Adolescents, and Adults: There are no dosage adjustments in the manufacturer&rsquo;s labeling; has not been studied. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223356\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chemet: 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223342\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062374\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Ensure adequate patient hydration; for patients who cannot swallow the capsule whole, immediately prior to administration open the capsule and sprinkle the medicated beads into a small amount of juice or on a small amount of apple sauce, ice cream, or soft food or placed on a spoon and followed with fruit drink to mask the odor (Howland 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6165884\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store between 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); avoid excessive heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062373\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of lead poisoning in patients with blood levels &gt;45 mcg/dL (FDA approved in ages &ge;1 year and adults); not indicated for prophylaxis of lead poisoning in a lead-containing environment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223392\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia (adults: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, drowsiness, fatigue, flank pain, headache, metallic taste, neuropathy, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (including herpetic lesion, mucocutaneous eruptions, papular rash), pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum cholesterol</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, decreased appetite, diarrhea, hemorrhoids, loose stools, mucositis, nausea, sore throat, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Decreased urine output (adults), difficulty in micturition (adults), proteinuria (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Change in platelet count (increase), eosinophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Candidiasis, common cold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, knee pain (adults), leg pain (adults), rib pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cloudy vision (cloudy film in eye), watery eyes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Blocked ear, otitis media</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, flu-like symptoms, nasal congestion, rhinorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hypersensitivity reaction (especially with retreatment), neutropenia (causal relationship not established)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223361\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to succimer or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223346\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Mild-to-moderate neutropenia has been reported; evaluate CBC with differential at baseline, weekly during treatment, and immediately upon the development of any sign of infection.  The manufacturer recommends withholding treatment for ANC &lt;1200/mm<sup>3</sup>; treatment may be cautiously resumed when ANC returns to baseline or &gt;1500/mm<sup>3</sup>. Consultation with a medical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Transient elevations in serum transaminases have been reported. Evaluate serum transaminases at baseline and weekly during treatment; more frequent monitoring may be required in patients with a history of liver disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Monitor for the development of allergic or other mucocutaneous reactions. A reversible mucocutaneous vesicular eruption of the oral mucosa, external urethral meatus, or perianal area has been reported (rarely).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Encephalopathy:  Succimer does not cross blood-brain barrier and should not be used to treat encephalopathy associated with lead toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to re-enter the contaminated environment until lead abatement has been completed. Primary care providers should consult experts in chemotherapy of heavy metal toxicity before using chelation drug therapy. Succimer is not used to prevent lead poisoning. A rebound rise in serum lead levels may occur after treatment as lead is released from storage sites into blood. The severity of rebound may guide the frequency of future monitoring and the need for additional chelation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Succimer is dialyzable; however, the lead chelates are not.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hydration: Adequate hydration should be maintained during therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300085\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12808&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223352\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6165840\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment. Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL. In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended. Encephalopathic pregnant women should be chelated regardless of trimester (CDC, 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062369\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood lead concentrations (baseline and weekly after treatment); liver enzymes (baseline and weekly during treatment; may require more frequent monitoring in patients with a history of liver disease), CBC with differential and platelets (baseline and weekly during therapy)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223345\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Succimer is an analog of dimercaprol. It forms water soluble chelates with heavy metals which are subsequently excreted renally. Succimer binds heavy metals; however, the chemical form of these chelates is not known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223360\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid but incomplete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Primarily extracellular (Aposhian, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;95% primarily to albumin (Aposhian, 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapidly and extensively to mixed succimer cysteine disulfides </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~3 hours (Aposhian, 1992) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~1-2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~25%) with peak urinary excretion between 2-4 hours (90% as mixed succimer-cysteine disulfide conjugates, 10% as unchanged drug); feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323897\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Chemet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,963.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038833\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Chemet (AT, BB, BM);</li>\n      <li>Succicaptal (CH, FR, GR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Environmental Health, &quot;Lead Exposure in Children: Prevention, Detection, and Management,&quot; <i>Pediatrics</i>, 2005, 116(4):1036-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-pediatric-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP). Low-level lead exposure harms children: A renewed call for primary intervention. January 4, 2012. Available at <a href=\"http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf\" target=\"_blank\">http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a> . Last accessed on March 17, 2017)</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chemet (succimer) [prescribing information]. Seymour, IN: Kremers Urban Pharmaceuticals, Inc.; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia RC and Snodgrass WR, &quot;Lead Toxicity and Chelation Therapy,&quot; <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-pediatric-drug-information/abstract-text/17189579/pubmed\" target=\"_blank\" id=\"17189579\">17189579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland MA. Antidotes in depth. <i>Goldfrank's Toxicologic Emergencies</i>. 10th ed. Hoffman RS, Howland MA, Lewin NA, et al, eds. New York, NY: McGraw-Hill; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mann KV and Travers JD, &ldquo;Succimer, An Oral Lead Chelator,&rdquo; <i>Clin Pharm</i>, 1991, 10(12):914-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-pediatric-drug-information/abstract-text/1663439/pubmed\" target=\"_blank\" id=\"1663439\">1663439</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12808 Version 66.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223371\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223372\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062370\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062364\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F223356\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F223342\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062374\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6165884\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062373\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F223392\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223361\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F223346\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300085\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F223352\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6165840\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062369\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F223345\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F223360\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323897\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038833\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12808|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-drug-information\" class=\"drug drug_general\">Dimercaptosuccinic acid (succimer): Drug information</a></li><li><a href=\"topic.htm?path=dimercaptosuccinic-acid-succimer-patient-drug-information\" class=\"drug drug_patient\">Dimercaptosuccinic acid (succimer): Patient drug information</a></li></ul></div></div>","javascript":null}